Sotera Wireless is a medical device company specializing in vital signs monitoring technology within the healthcare sector. The company offers a patient monitoring system that provides continuous, real-time tracking of key health indicators such as blood pressure, oxygen saturation, respiration, pulse, ECG, posture, and arrhythmias. The system is primarily used in general care settings for early detection of patient deterioration. Sotera Wireless was formerly known as Triage Wireless. It was founded in 2004 and is based in San Diego, California.

Cardiophotonics develops non invasive blood monitors used to detect cardiac arrhythmia and dehydration

Speckodyne Corp aims to be a provider of continuous real-time blood coagulability monitoring technology in Operation Room, Catheterization Lab or Intensive Care Unit settings. Based on a approach developed at UCF's College of Optics & Photonics, Speckodyne's blood coagulability monitor uses optical fiber and solid-state optics technology, leading to a robust, relatively inexpensive design that can be easily integrated with existing interventional devices such as catheters and guidewires, as well as bed-side or laboratory equipment.

GlySure focuses on medical technology within the healthcare sector, specifically developing continuous intravascular glucose monitoring systems. Its system is designed to support tight glycemic control (TGC) in hospital intensive care units by providing accurate and continuous monitoring of glucose levels. GlySure's technology addresses the challenges of managing blood glucose in critically ill patients and aims to reduce complications such as sepsis and renal failure. It was founded in 2006 and is based in Abingdon, United Kingdom.

SonoMedix is developing a device to monitor blood coagulation and hemostatic status, using NanoAcoustic Blood Analyzer (NABA) technology licensed from Drexel University. SonoMedix is developing a working NABA-based prototype of a device to be used at home to measure the prothombin time, a measure of blood coagulation, in patients taking the anticoagulant drug, warfarin (Coumadin ). The device will allow the patients who need to perform this testing to use a smaller amount of blood than currently marketed devices, which will allow them to obtain blood from sites other than fingers, reducing the pain of obtaining the sample. The small sample size is currently being validated.

Cellatope uses a platform, CB-CAPs (Cell-Bound Complement Activation Products), to develop an early identification and monitoring solution for autoimmune diseases